Xenon Pharmaceuticals Inc.
XENEHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeXenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric. With a market capitalization of $6.60B, it sits in mid-cap territory. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Market Cap
$6.60B
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
-13.63
EPS (TTM)
$-4.79
EPS (Fwd)
$-5.01
ROE
-37.5%
ROA
-24.2%
Cash
$1.09B
Total Debt
$7.5M
Free CF
-$186.3M
52W Change
116.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.09B in cash comfortably exceeding the $7.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$186.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -37.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $9.4M (2022) to $7.5M (2025), a 21% decline worth watching.
XENE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, XENE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing XENE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.